Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Overweight at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a neutral rating to an overweight rating in a research report released on Monday morning, Marketbeat.com reports. The brokerage currently has $328.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $280.00.

ALNY has been the topic of several other research reports. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Royal Bank of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $312.30.

Alnylam Pharmaceuticals Stock Up 2.6 %

Shares of ALNY opened at $290.70 on Monday. The company has a market capitalization of $37.63 billion, a P/E ratio of -133.96 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The business’s 50 day simple moving average is $257.81 and its 200-day simple moving average is $260.02. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Colonial Trust Co SC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.